METABOLIC
MAGNETIC RESONANCE IMAGING
NVision Imaging is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
THIS IS POLARIS
Hyperpolarization enables rapid, precise measurement of natural metabolites by standard MRIs. NVision provides fast, robust, and easy-to-use hyperpolarization technology for preclinical and clinical research and clinical applications. Learn more
POLARIS OFFERS:
High throughput (3min per dose)
Convenient, room temperature processing
Small footprint, no infrastructure adjustment
Simple, robust workflow
METABOLIC MRI PROVIDES UNPRECEDENTED INSIGHTS AT CELLULAR LEVEL.
vs
Standard MRI
Detects slow-changing effects at tissue level.
Metabolic MRI
Detects early changes of key metabolic pathways at cellular level.
WE HAVE DEVELOPED A UNIQUE QUANTUM-BASED PLATFORM THAT TRANSFORMS EXISTING MRIS INTO POWERFUL METABOLIC IMAGERS AT SCALE.
1
PREPARE
Take precursor metabolic agent (natural to the body),
e.g., 13C-pyruvate
2
POLARIZE
Use POLARIS to rapidly enhance the MRI signal of the metabolic agent > 10,000x, making it visible to the MRI
3
SCAN
Inject the hyperpolarized metabolite and image with standard, i.e. existing MRI
METABOLIC MRI ADDS CRITICAL INFORMATION FOR ASSESSING TUMOROUS ACTIVITY AND VIABILITY BASED ON METABOLISM
IN LESS THAN 30 SECONDS.
METABOLIC INSIGHTS AT CELLULAR LEVEL ALLOW EARLIEST ASSESSMENT OF RESPONSE TO CANCER THERAPY.
vs
Changes at tissue level
​
Typically, changes are visible
only months after onset
of treatment.
Changes at cellular level
​
Effective treatment induces metabolic response in tumor
cells within days, visible with Metabolic MRI.
METABOLIC MRI FOR ADAPTIVE CANCER TREATMENT
Differentiation between resistant and sensitive tumors within days by means of Metabolic MRI: Patients who are found to have resistant tumors can shift to a combination therapy or alternate drug, whereas patients who are found to have sensitive tumors can confidently continue with the same treatment - but with certainty.
~ 7 days
PATIENT GROUP
METABOLIC MRI
PRE-TREATMENT
TREATMENT
METABOLIC MRI
POST-TREATMENT
DIFFERENTIATION:
RESISTANT / SENSITIVE
ADJUSTED TREATMENT
HIGH IMPACT ACROSS MANY MEDICAL FIELDS - IN ONCOLOGY AND BEYOND
Oncology
Oncology
​Treatment response assessment, early diagnosis and non-invasive assessment of tumor aggressiveness.
Cardiology
Cardiology
​
Improved diagnosis and guidance of intervention in ischemic heart disease, and monitoring treatment response in heart failure patients.
Hepatology
Hepatology
​
Early diagnosis and treatment response assessment for nonalcoholic steatohepatitis (NASH).
Nephrology
Nephrology​
​
Assessment of etiology and treatment response in chronic and acute kidney failure.
Neurology
Neurology
​
Early diagnosis and treatment response assessment over a wide range of neurodegenerative, inflammatory, ischemic, and traumatic conditions.
Rheumatology
Rheumatology
​
Early diagnosis and treatment response assessment for inflammatory arthritis and other inflammatory conditions.
THE TEAM
FOUNDING TEAM
Sella Brosh, M.D.
Chief Executive Officer
Dr. Ilai Schwartz
Co-Founder & CTO
Prof. Martin Plenio
Co-Founder
Prof. Fedor Jelezko
Co-Founder
Prof. Alex Retzker
Co-Founder
INVESTORS
NVision is funded by deep-tech investors and highly-competitive grants,
collaborating with top-tier medical and research units in US and EU
Lauder
FOR MORE INFORMATION
CONNECT WITH US
FEATURES IN LEADING JOURNALS
AND PRESS RELEASES
